Login to Your Account

Eylea blinks and Novartis looks to face-off in nAMD with brolucizumab

By Marie Powers
News Editor

Tuesday, June 20, 2017

Novartis AG put its VEGF-A ligand inhibitor, brolucizumab, to the test in neovascular age-related macular degeneration against Regeneron Pharmaceuticals Inc.'s cash cow, Eylea, and appeared to come up a winner.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription